INLIF (INLF) shares were down 43% in Thursday premarket activity, extending the previous session's 88% decline.
Sleep Number (SNBR) stock was down 40% after the company said in a regulatory filing that it received a Nasdaq delisting notice related to its Chapter 11 filing and associated public interest and compliance concerns.
NovoCure (NVCR) shares were down 21% after a phase 3 trial evaluating its Tumor Treating Fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.
Elicio Therapeutics (ELTX) stock was down 20%, following Wednesday's 70% gain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments